5TH ASIA-PACIFIC PHARMACOVIGILANCE TRAINING COURSE

4th – 15th March 2019
Ghaziabad, New Delhi, India
Building a global safety culture

The 5th Asia-Pacific Pharmacovigilance Training Course will take place in Ghaziabad, New Delhi, India, 4th – 15th March 2019.

Adverse drug reactions (ADRs) are a major public health problem and drug safety monitoring is of paramount importance to public health. An understanding of the clinical aspects of ADRs and the principles of drug safety are fundamental requirements for any professional working in the fields of pharmacovigilance or patient care.

This course provides a solid practical foundation for those working in drug safety as well as the latest knowledge and thinking for experienced staff.

The course’s aim is to develop pharmacovigilance knowledge and skills in the Asia-Pacific region. Four Asia-Pacific Pharmacovigilance training courses were successfully conducted during the last four years at JSS University, Mysuru. Healthcare professionals from 20 different countries participated and benefited from the courses. This year the course will be held in Ghaziabad, New Delhi.

The course focuses on essential topics including:
- pharmacovigilance best practices
- signal detection
- regulatory aspects
- reporting culture
- pharmacovigilance in public health
- benefit/harm assessment
- pharmacovigilance tools.

Programme outline

The course draws on the 20 years of experience Uppsala Monitoring Centre has in providing education and training to a global network of pharmacovigilance experts and healthcare professionals. The Asia-Pacific course is tailored to regional needs and addresses challenges unique to this area. The purpose of the course is to further develop effective and sustainable pharmacovigilance practices for member countries of the WHO Programme for International Drug Monitoring (WHO PIDM) and individuals involved in the field by creating a unique opportunity for learning and collaboration.

The programme includes a management component designed to help participants improve their capacity to influence sustainable change in their countries. Issues related to health economics, communication, fundraising and risk management will be covered. For detailed information, please visit: www.who-umc.org or www.5thasiapacificpvtraining.com.

Lectures, hands-on training sessions and workshops will take place in an open and interactive environment. Plenty of opportunities to interact with Pharmacovigilance Programme of India (PvPI), Indian Pharmacopoeia Commission (IPC), JSS University and UMC staff, faculty experts and fellow course participants will be provided. All participants will be given access to pre-course reading materials.

Interested?

This two-week course is tailored for representatives of national pharmacovigilance centres, ministries of health and public health programmes as well as healthcare professionals – physicians, pharmacists, nurses – from health authorities or academic or industry settings. Participants should be fluent in English and have some experience in the pharmacovigilance field.

Course fee

The course fee is 1,500 USD for public/academic sector representatives and 2,000 USD for industry sector representatives. This fee includes breakfast, coffee/tea, lunches during course days, course material, accommodation and social activities. Airfares, dinner, per diem and health insurance are the responsibility of each participant or sponsoring organization. Social activities and events include a course dinner and sightseeing tours.

How to apply?

The admission committee selects individuals committed to patient safety who can contribute actively during these two weeks. We encourage you to start the application process as soon as possible; the course is designed for a maximum of 30 people.

Please submit your application via the electronic form available on the PvPI, IPC website: www.5thasiapacificpvtraining.com by 1st November 2018.

Faculty

International pharmacovigilance experts from WHO, WHO Collaborating Centres, UMC, JSS University, PvPI, IPC, Indian Drug Regulatory Authority, and from universities, academic institutions and the pharmaceutical industry across India will lead the sessions.

About the venue

A symbol of the country’s rich past and thriving present, Delhi is a city where ancient and modern blend seamlessly together. New Delhi is teeming with ancient monuments and remnants of structures that speak volumes of glorious history. Along with car-fringed avenues, brilliant billboards, and huge traffic on roads, the historical sites contribute to the essence of the city’s diverse culture. Delhi is bounded by four states namely Haryana, Rajasthan, Uttar Pradesh and Punjab that have a strong influence on the lifestyle of Delhi. Delhi is a cosmopolitan city where people are open to embracing new ideas and lifestyle. People from all parts of the country live here. All major festivals of India are celebrated and the Unity in Diversity is evident in social and cultural gatherings.

Discover more about Delhi on website http://delhitourism.gov.in/delhitourism/index.jsp

Queries

If you have any questions please visit http://www.ipc.gov.in/PvPI/pv_home.html or contact the course management via e-mail us pvasiapacific@gmail.com.

Address: Indian Pharmacopoeia Commission Sector 23, Raj Nagar, Ghaziabad -201002 India

“UMC has a vision of a world where all patients and health professionals make wise therapeutic decisions in their use of medicines.”
About Uppsala Monitoring Centre

Uppsala Monitoring Centre (UMC) advances the science of pharmacovigilance and inspires patient safety initiatives all over the world.

As an independent, non-profit foundation, UMC engages stakeholders who share their vision and collaborates to build a global patient safety culture. As a leader in the research and development of new scientific methods, UMC explores the benefits and risks of medicines to help minimise harm to patients, and offers products and services used by health authorities and life-science companies worldwide. For almost 40 years, UMC has provided scientific leadership and operational support to the WHO Programme for International Drug Monitoring.

About Indian Pharmacopoeia Commission

The Indian Pharmacopoeia Commission (IPC) was established as an Autonomous Institution under the Ministry of Health & Family Welfare, Government of India, primarily with the objectives of regularly updating the Indian Pharmacopoeia (an official book of standards for drugs) by publishing new editions and its addenda, the National Formulary of India (a reference book for rational use of medicines), besides providing IP Reference Substances/Impurity standards and training for stakeholders on pharmacopoeial issues. IPC is the first WHO prequalified government organization in India in the area of physical and chemical analysis of active pharmaceutical ingredients (APIs) and finished pharmaceutical products. IPC functions as a National Coordination Centre (NCC) for the Pharmacovigilance Programme of India (PvPI) and Materiovigilance Programme of India (MvPI), to safeguard the health of the Indian population. IPC is designated as a WHO Collaborating Centre for Pharmacovigilance in Public Health Programmes and Regulatory Services.

Contact UMC

Address: Box 1051, SE-751 40
Uppsala, Sweden
Telephone: +46 18 65 60 60
Fax: +46 18 65 60 80
Email: pvtraining@who-umc.org

Follow UMC on social media:

twitter.com/UMCGlobalSafety
facebook.com/UppsalaMonitoringCentre
linkedin.com/Company/Uppsala-Monitoring-Centre
youtube.com/c/UppsalaMonitoringCentre

INSPIRE. ENGAGE. TRANSFORM.